WO1997016064A1 - Procedes et compositions de reduction du rejet de xenogreffe - Google Patents

Procedes et compositions de reduction du rejet de xenogreffe Download PDF

Info

Publication number
WO1997016064A1
WO1997016064A1 PCT/US1996/017695 US9617695W WO9716064A1 WO 1997016064 A1 WO1997016064 A1 WO 1997016064A1 US 9617695 W US9617695 W US 9617695W WO 9716064 A1 WO9716064 A1 WO 9716064A1
Authority
WO
WIPO (PCT)
Prior art keywords
transgenic
cells
cell
human
organs
Prior art date
Application number
PCT/US1996/017695
Other languages
English (en)
Other versions
WO1997016064A9 (fr
Inventor
Yiannis Ioannou
Robert J. Desnick
Mauro S. Sandrin
Ian F. C. Mckenzie
Original Assignee
The Mount Sinai Medical Center
The Austin Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mount Sinai Medical Center, The Austin Research Institute filed Critical The Mount Sinai Medical Center
Priority to EP96939544A priority Critical patent/EP0877549A4/fr
Priority to JP09517615A priority patent/JP2000514641A/ja
Priority to AU76686/96A priority patent/AU7668696A/en
Priority to IL12429396A priority patent/IL124293A0/xx
Publication of WO1997016064A1 publication Critical patent/WO1997016064A1/fr
Publication of WO1997016064A9 publication Critical patent/WO1997016064A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des procédés et des compositions de réduction du rejet de xénogreffes. De façon spécifique, l'invention concerne principalement des cellules, des tissus, des organes et des animaux transgéniques contenant des molécules d'acides nucléiques transgéniques dirigeant l'expression de produits géniques incluant, entre autres, des enzymes capables de modifier directement ou indirectement les épitopes des glucides de la surface des cellules, de façon que ces épitopes de glucides ne soient plus reconnus par les anticorps humains naturels ou par la réponse immunitaire à médiation cellulaire de l'homme. On arrive ainsi à réduire la réponse du système immunitaire humain mise en évidence par la présence de tels épitopes de glucides. Selon une réalisation préférée, les cellules, tissus, organes et animaux transgéniques expriment des molécules d'acides nucléiques codant l'enzyme fonctionnelle α-Galactosidase A (α-GalA) recombiné qui modifie l'épitope de glucide Galα(1,3)Gal. Selon un mode de réalisation plus préférentiel, les cellules, tissus, organes et animaux transgéniques exprimant l'α-GalA fonctionnelle recombiné sont des cellules, des organes, des tissus et/ou des animaux transgéniques d'origine ou de nature porcine. L'invention concerne également des techniques de xénogreffe consistant à introduire, chez un receveur humain, des cellules, tissus et/ou organes transgéniques de façon à constater chez de tels receveurs humains un niveau de rejet hyperaigu inférieur au niveau de rejet hyperaigu observé chez les receveurs humains ayant reçu des cellules, tissus et/ou organes non transgéniques.
PCT/US1996/017695 1995-11-03 1996-11-01 Procedes et compositions de reduction du rejet de xenogreffe WO1997016064A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96939544A EP0877549A4 (fr) 1995-11-03 1996-11-01 Procedes et compositions de reduction du rejet de xenogreffe
JP09517615A JP2000514641A (ja) 1995-11-03 1996-11-01 異種移植拒絶を低減するための方法および組成物
AU76686/96A AU7668696A (en) 1995-11-03 1996-11-01 Methods and compositions for the reduction of xenotransplantation rejection
IL12429396A IL124293A0 (en) 1995-11-03 1996-11-01 Method and compositions for the reduction of xenotransplantation rejection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US620095P 1995-11-03 1995-11-03
US60/006,200 1995-11-03

Publications (2)

Publication Number Publication Date
WO1997016064A1 true WO1997016064A1 (fr) 1997-05-09
WO1997016064A9 WO1997016064A9 (fr) 1997-08-28

Family

ID=21719767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017695 WO1997016064A1 (fr) 1995-11-03 1996-11-01 Procedes et compositions de reduction du rejet de xenogreffe

Country Status (5)

Country Link
EP (1) EP0877549A4 (fr)
JP (1) JP2000514641A (fr)
AU (1) AU7668696A (fr)
IL (1) IL124293A0 (fr)
WO (1) WO1997016064A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021415A1 (fr) * 1997-10-28 1999-05-06 Stem Cell Sciences Pty. Ltd. Transfert nucleaire pour la production d'un embryon d'animal transgenique
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US7547522B2 (en) 2002-08-14 2009-06-16 Immerge Biotherapeutics, Inc. Method to enrich for α(1,3)-galactosyltransferase null pig cells
US7560538B2 (en) 2003-11-05 2009-07-14 University Of Pittsburgh Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region
US7795493B2 (en) 2002-08-21 2010-09-14 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase
WO2011012297A1 (fr) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Traitement enzymatique d'anticorps
US8106251B2 (en) 2002-08-21 2012-01-31 Revivicor, Inc. Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
WO2013050335A1 (fr) 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Procédé de production d'anticorps de glycoforme g1
US9187564B2 (en) 2010-10-05 2015-11-17 Hoffmann-La Roche Inc. Antibodies against human TWEAK and uses thereof
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
WO1995028412A1 (fr) * 1994-04-13 1995-10-26 Biotransplant, Inc. PORC NEGATIF POUR L'α(1,3) GALACTOSYLTRANFERASE
AU2828595A (en) * 1994-06-15 1996-01-05 Alexion Pharmaceuticals, Inc. Methods for reducing hyperacute rejection of xenografts

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN C.G., ET AL.: "REDUCTION IN GAL-ALPHA 1,3-GAL EPITOPE EXPRESSION IN TRANSGENIC MICE EXPRESSING HUMAN H-TRANSFERASE.", XENOTRANSPLANTATION, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 03., 1 January 1996 (1996-01-01), US, pages 69 - 75., XP000909895, ISSN: 0908-665X *
KANNAGI K.C., ET AL.: "INTRODUCTION OF ALPHA(1,2)-FUCOSYLTRANSFERASE AND ITS EFFECT ON ALPHA-GAL EPITOPES IN TRANSGENIC PIG.", XENOTRANSPLANTATION, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 03., 1 January 1996 (1996-01-01), US, pages 81 - 86., XP000909894, ISSN: 0908-665X *
KOIKE C., ET AL.: "CONVERTING ALPHA-GAL EPITOPE OF PIG INTO H ANTIGEN.", TRANSPLANTATION PROCEEDINGS, ELSEVIER INC., ORLANDO, FL; US, vol. 28., no. 02., 1 January 1996 (1996-01-01), ORLANDO, FL; US, pages 553., XP000909889, ISSN: 0041-1345 *
SANDRIN M.S., ET AL.: "REDUCTION OF THE MAJOR PORCINE XENOANTIGEN GAL ALPHA(1,3)GAL BY EXPRESSION OF ALPHA(1,2)FUCOSYLTRANSFERASE.", XENOTRANSPLANTATION, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 03., no. 01., 1 January 1996 (1996-01-01), US, pages 134 - 140., XP000909854, ISSN: 0908-665X *
See also references of EP0877549A4 *
SHARMA A., ET AL.: "REDUCTION IN THE LEVEL OF GAL(ALPHA 1,3)GAL IN TRANSGENIC MICE AND PIGS BY THE EXPRESSION OF AN ALPHA(1,2)FUCOSYLTRANSFERASE.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93., 1 January 1996 (1996-01-01), US, pages 7190 - 7195., XP000910139, ISSN: 0027-8424, DOI: 10.1073/pnas.93.14.7190 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021415A1 (fr) * 1997-10-28 1999-05-06 Stem Cell Sciences Pty. Ltd. Transfert nucleaire pour la production d'un embryon d'animal transgenique
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US7547522B2 (en) 2002-08-14 2009-06-16 Immerge Biotherapeutics, Inc. Method to enrich for α(1,3)-galactosyltransferase null pig cells
US10130737B2 (en) 2002-08-21 2018-11-20 Revivicor, Inc. Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
US7795493B2 (en) 2002-08-21 2010-09-14 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase
US11172658B2 (en) 2002-08-21 2021-11-16 Revivicor, Inc. Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase
US8106251B2 (en) 2002-08-21 2012-01-31 Revivicor, Inc. Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
US10912863B2 (en) 2002-08-21 2021-02-09 Revivicor, Inc. Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
US7560538B2 (en) 2003-11-05 2009-07-14 University Of Pittsburgh Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region
US8524470B2 (en) 2009-07-30 2013-09-03 Hoffman-La Roche, Inc. Enzymatic antibody processing
WO2011012297A1 (fr) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Traitement enzymatique d'anticorps
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9187564B2 (en) 2010-10-05 2015-11-17 Hoffmann-La Roche Inc. Antibodies against human TWEAK and uses thereof
WO2013050335A1 (fr) 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Procédé de production d'anticorps de glycoforme g1

Also Published As

Publication number Publication date
JP2000514641A (ja) 2000-11-07
EP0877549A1 (fr) 1998-11-18
EP0877549A4 (fr) 2002-01-02
IL124293A0 (en) 1998-12-06
AU7668696A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
US6790639B2 (en) Mammalian osteoregulins
JP4243355B2 (ja) 細胞膜に固定された抗凝固性融合タンパク質
US6455037B1 (en) Cells expressing an αgala nucleic acid and methods of xenotransplantation
JP2009219499A (ja) 遺伝子破壊、それに関連する組成物および方法
JP2002512524A (ja) 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ
WO1997016064A1 (fr) Procedes et compositions de reduction du rejet de xenogreffe
WO1997016064A9 (fr) Procedes et compositions de reduction du rejet de xenogreffe
JPH10504707A (ja) 異種移植片の超急性拒否反応を減少させる方法
Charreau et al. Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates
AU6970700A (en) Method and compositions for the reduction of xenotransplantation rejection
AU712016B2 (en) Ikaros transgenic cells and animals
US20060078550A1 (en) Porcine fgl2
US6419921B1 (en) DNA-constructs of blood clotting factors and P-Selectin
US20050005317A1 (en) Expression of zebrafish bone morphogenetic protein 4
JP2000516804A (ja) トランスジェニック非ヒト哺乳動物臓器のヒトへの移植の目的のためのそれらの調製方法およびその方法を実施するためのヌクレオチド配列
EP1010762A1 (fr) Constructions d'ADN comprenant des facteurs de coagulation sanguine et la P-sélectine
JP2002058486A (ja) エストロゲン高感受性メダカ
US6794186B2 (en) pCAR and its uses
Murakami et al. Porcine MCP gene promoter directs high level expression of human DAF (CD55) in transgenic mice
WO2002081688A1 (fr) Molecules d'adn codant pour la synthase d'igb3, et ses utilisations pour l'interruption des genes de glycosyltransferase dans des tissus et organes de xenogreffe
CA2444607A1 (fr) Gene <i>progeniteur pancreatique 1 </i>et ses utilisations
KR100427299B1 (ko) 인체 골 재흡수 억제인자（ｈＯＰＧ）를 생산하는 재조합플라스미드 ｐＧＨＯＰＧ（ＫＣＴＣ １０１９ＢＰ）
CN117043324A (zh) 用于治疗先天性肌营养不良的治疗性lama2载荷
Kim et al. Knock-in Somatic Cells of Human Decay Accelerating Factor and α1, 2-Fucosyltransferase Gene on the α1, 3-Galactosyltransferase Gene Locus of Miniature Pig
WO2001025425A1 (fr) Adn helicase de type recq5 localisee dans le noyau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU IL JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1996939544

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996939544

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996939544

Country of ref document: EP